Dose Response Study of Patients With Erythematous Rosacea

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the dose-response relationship (effect) of four concentrations of V-101 Cream in patients with erythematous(redness) rosacea.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vicept Therapeutics, Inc.
• Collaborator: Accenture

Criteria

Inclusion Criteria:

• male or females at least 18 years of age

• diagnosis of stable erythematous rosacea

• < 3 inflammatory lesions

• in good general health

• females must be non-pregnant and non-lactating

• must be willing to sign a consent form

Exclusion Criteria:

• have ocular, phymatous or other types of rosacea

• allergy to any ingredient in study drug

• participation in other investigational studies within 30 days of enrollment

• use of systemic steroids within 28 days of Baseline

• use of tetracycline antibiotics within 28 days of baseline

• use of products containing oxymetazoline within 14 days of baseline

• use of topical steroids witin treatment area 14 days prior to baseline

• use of Rx or OTC products for treatment of acne or rosacea within 14 days of baseline

• use of any product for reducing redness within the treatment area witin 14 days prior to baseline

• use of monoamine oxidase (MAO) inhibitors

• use of niacin >/= 500mg/day